Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

An estimated 2.9 million people worldwide live with multiple sclerosis, a chronic and lifelong disease. It disproportionately affects women.

Roche Holding's Genentech unit said the Food and Drug Administration approved its twice-yearly, subcutaneous injection treatment for patients with two types of multiple sclerosis. The treatment, ...

Multiple sclerosis (MS) is a disabling ... or Class III/IV heart failure or have a presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or ...

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...